{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.4","upperLimit":"14.74","value":"10.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"}],"units":"Participants"}],"description":"Progression free survival (PFS) was defined as the time from registration to progression or death of any cause. Progression free and alive patients were censored at the date of last clinical assessment. The median PFS with 95% CI was estimated using the Kaplan Meier method.\n\nProgression is defined as\n\n* For patients with \\<5% bone marrow blasts: ≥50% increase in blasts to \\>5% blasts\n* For patients with 5-10% bone marrow blasts: ≥50% increase to \\>10% blasts\n* For patients with 10-19% bone marrow blasts: increase to ≥20% blasts\n* One or more of the following: 50% or greater decrement from maximum remission/response levels in ANC \\< 1.5 K/L or PLT\\< 100 K/L, or reduction in HGB by at least 2 g/dL or becoming transfusion dependent\n\nProgression after HI: Includes one or more of the following\n\n* Decrement of 50% or greater from maximum response levels in ANC \\< 1.5 K/L or PLT \\< 100 K/L\n* Reduction in HGB concentration by at least 2 g/dL\n* Becoming transfusion dependent","dispersionType":"95% Confidence Interval","groups":[{"description":"Adult patients with MDS receive treatment with vatalanib.\n\nvatalanib: Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or \\> tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)","id":"OG000","title":"Vatalanib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Duration of study (up to 5 years)","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"months"}